732 related articles for article (PubMed ID: 12185503)
41. [The clinical significance of M proteins].
Sasaki R
Rinsho Byori; 2001 Jul; 49(7):678-81. PubMed ID: 11519130
[TBL] [Abstract][Full Text] [Related]
42. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
43. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
[TBL] [Abstract][Full Text] [Related]
44. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
[TBL] [Abstract][Full Text] [Related]
45. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
[TBL] [Abstract][Full Text] [Related]
46. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
48. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Zangari M; Berno T; Zhan F; Boucher KM; Tricot G; Fink L
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance.
Rossi D; De Paoli L; Franceschetti S; Capello D; Vendramin C; Lunghi M; Conconi A; Magnani C; Gaidano G
Br J Haematol; 2007 Jul; 138(2):249-52. PubMed ID: 17535272
[TBL] [Abstract][Full Text] [Related]
50. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population.
Park HK; Lee KR; Kim YJ; Cho HI; Eun Kim J; Woong Kim K; Jung Kim Y; Lee KW; Hyun Kim J; Bang SM; Lee JS
Am J Hematol; 2011 Sep; 86(9):752-5. PubMed ID: 21786289
[TBL] [Abstract][Full Text] [Related]
52. [Benign monoclonal gammopathy].
Shirota T; Kondo M; Uchida H; Ito H
Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
[TBL] [Abstract][Full Text] [Related]
53. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
[TBL] [Abstract][Full Text] [Related]
54. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.
Rosiñol L; Cibeira MT; Montoto S; Rozman M; Esteve J; Filella X; Bladé J
Mayo Clin Proc; 2007 Apr; 82(4):428-34. PubMed ID: 17418070
[TBL] [Abstract][Full Text] [Related]
55. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings.
Bizzaro N; Pasini P
Haematologica; 1990; 75(1):58-63. PubMed ID: 2110928
[TBL] [Abstract][Full Text] [Related]
56. Monoclonal gammopathy of undetermined significance: a consensus statement.
Berenson JR; Anderson KC; Audell RA; Boccia RV; Coleman M; Dimopoulos MA; Drake MT; Fonseca R; Harousseau JL; Joshua D; Lonial S; Niesvizky R; Palumbo A; Roodman GD; San-Miguel JF; Singhal S; Weber DM; Zangari M; Wirtschafter E; Yellin O; Kyle RA
Br J Haematol; 2010 Jul; 150(1):28-38. PubMed ID: 20507313
[TBL] [Abstract][Full Text] [Related]
57. [50-year-old man with fatigue and monoclonal gammopaty].
Raeder H; Kildahl-Andersen O; Stalsberg H
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2677-9. PubMed ID: 17972388
[TBL] [Abstract][Full Text] [Related]
58. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
59. [Monoclonal gammopathies of undetermined significance called "MGUS"].
Clément F
Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
[TBL] [Abstract][Full Text] [Related]
60. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
